Clinical trials: Rash Due to Epidermal Growth Factor Receptor Inhibitors
- Condition Rash Due to Epidermal Growth Factor Receptor Inhibitors
- Funder type Industry (pharma, biotech, devices)
Rash Due to Epidermal Growth Factor Receptor Inhibitors
Safety, Tolerability and Efficacy Study of Doxycycline Foam for the Prevention of EGFRI Skin Toxicity in Cancer Patients
The purpose of this study is to evaluate the safety, tolerability and efficacy of FDX104 Antibiotic Foam in the prevention of EGFRI skin toxicity in cancer patients receiving Cetuximab or Panitumumab.
- Trial name
- NCT02239731
- Testing
- FDX104 (4% Doxycycline)
- Where
- 7 sites in Israel
- Volunteers
- 24 people
- Sponsor
- Vyne Therapeutics Inc.